Investor Overview

PTI (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$10.50
Change (%) Stock is Up 0.20 (1.94%)
Volume146,748
Data as of 12/02/16 4:00 p.m. ET
Corporate Profile

Proteostasis Therapeutics, Inc. is an innovative biopharmaceutical company committed to the discovery and development of novel therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. Our initial therapeutic focus is on cystic fibrosis, or CF, which is caused by defects in the cystic fibrosis transmembrane conductance regulator, or CFTR, protein and insufficient CFTR protein function. ... More >>

Recent NewsMore >>
Proteostasis Therapeutics Reports Third Quarter 2016 Financial Results
November 10, 2016
Read More


Proteostasis Therapeutics Announces Conference Call to Provide Clinical and Scientific Update at 30th Annual North American Cystic Fibrosis Conference
October 26, 2016
Read More


Proteostasis Therapeutics Appoints Naimish Patel, M.D., C.M., and Elizabeth Tullis, M.D., FRCPC, to its Clinical Advisory Board
September 28, 2016
Read More


Upcoming EventsMore >>
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed.
INVESTORS & MEDIA